|
|
||||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the Rehabilitation Unit (Drs. Winck and Almeida, Mr. Gonçalves, Ms. Lourenço, and Mr. Viana), Pneumology Department, Hospital São João, Faculdade de Medicina, Universidade do Porto-Porto, Portugal; and Department of Physical Medicine and Rehabilitation (Dr. Bach), University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, NJ.
Correspondence to: João Carlos Winck, MD, PhD, Pneumology Department, Hospital São João, Faculdade de Medicina, Universidade do Porto-Porto, Portugal; e-mail: jwinck{at}hsjoao.min-saude.pt
| Abstract |
|---|
|
|
|---|
Design: Prospective clinical trial.
Setting: Rehabilitation unit of a university hospital.
Patients or participants: Thirteen patients with amyotrophic lateral sclerosis (ALS), 9 patients with severe COPD, and 7 patients with other neuromuscular disorders (oNMDs) with chronic airway secretion encumbrance and decreases in oxyhemoglobin saturation (SpO2).
Interventions: Pressures of MI-E of 15 cm H2O, 30 cm H2O, and 40 cm H2O were cycled to each patient, with 3 s for insufflation and 4 s for exsufflation. One application was six cycles at each pressure for a total of three applications.
Measurements and results: We continuously evaluated respiratory inductance plethysmography (RIP) and SpO2 during every application. Peak cough flow (PCF) and dyspnea (Borg Scale) were also measured before the first and after the last application. The technique was well tolerated in all patient groups. Median SpO2 improved significantly (p < 0.005) in all patient groups. Median PCF improved significantly (p < 0.005) in the ALS and oNMD groups from 170 to 200 L/min and from 180 to 220 L/min, respectively, and dyspnea improved significantly in the patients with oNMDs and patients with COPD from 3 to 1 and from 2 to 0.75, respectively. Breathing pattern characteristics (RIP) did not deteriorate after MI-E in any patient groups. Inspiratory flow limitation significantly decreased at the highest MI-E pressures for the ALS group.
Conclusions: Our results confirm good tolerance and physiologic improvement in patients with restrictive disease and in patients with obstructive disease, suggesting that MI-E may be a potential complement to noninvasive ventilation for a wide variety of patient groups.
Key Words: amyotrophic lateral sclerosis COPD cough flow mechanical insufflation-exsufflation neuromuscular disorders oxygen saturation respiratory inductive plethysmography
| Introduction |
|---|
|
|
|---|
Cough flows have value in predicting successful extubation and mortality rate in patients with neuromuscular disorders and COPD.45 Cough augmentation with mechanical insufflation-exsufflation (MI-E) produces a significant increase in PCF and facilitates airway secretion clearance in NMDs.67 It has been reported to be successful in avoiding hospitalizations, pneumonias, episodes of respiratory failure, and tracheotomy for patients with Duchenne muscular dystrophy,8 spinal muscular atrophy,9 and ALS.1
With regard to COPD, although earlier publications10 described some benefit, Sivasothy et al11 reported that MI-E decreased PCF and resulted in no subjective benefit, suggesting that it may even exacerbate hyperinflation. However, only low pressures were used in this study, and higher pressures were used in the more successful studies.712 The aim of the present study was to evaluate the tolerance and effect of various pressure settings of MI-E on breathing pattern, PCF, and oxygen saturation for patients with COPD or NMDs.
| Methods and Materials |
|---|
|
|
|---|
Four patients with COPD received long-term oxygen therapy and continued it during the study; one patient received NPPV, and three patients received both long-term oxygen therapy and NPPV. The ALS group included 10 patients with severe bulbar involvement; 11 patients with ALS received NPPV. The oNMD group included four patients with myotonic dystrophy, one patient with Duchenne muscular dystrophy, and two patients with other muscular dystrophies. Six of the seven patients received NPPV. Demographic data are shown in Table 1 .
|
Spirometry, MIP, maximal expiratory pressure, and resting awake blood gases from radial artery samples (RapidLab 860; Ciba-Corning; Sudburry, England) were measured before the first application in the morning with the patient spontaneously breathing room air. Dyspnea and PCF were measured before the first and after the last application. Respiratory inductive plethysmography (RIP) was measured during all applications.
MI-E Settings
Mechanical cough assistance was provided by using the Cough-Assist device (JH Emerson Company; Cambridge, MA). The pressures are generated by a two-stage centrifugal blower. The positive and negative pressures may be set for insufflation and exsufflation, up to a maximum of 60 cm H2O.17 For each patient, each application was six insufflation-exsufflation cycles at each of the following pressures: 15 to 15 cm H2O, 30 to 30 cm H2O, and 40 to 40 cm H2O.
The timing of the cycle was 3-s insufflation, 4-s exsufflation, and a postexsufflation 4-s pause. There was a 2-min rest period between each application, during which the RIP measurements were obtained. During exsufflation, ALS and oNMD patients were actively told to cough, while patients with COPD were advised to exhale slowly. After the sixth insufflation to 40 cm H2O of the last application, the subjects were asked to cough forcefully on their own, as described by Barach et al.18
Quantitative RIP
RIP was recorded using the SomnoStar PT device (SensorMedics). The input leads for RIP consisted of two cloth belts that covered curved wires encircling the chest and abdomen. Initial calibration of the ribcage and abdominal signals were performed during the first 5 min of operation using a qualitative diagnostic calibration procedure.19 A software program (RespiEvents version 4.2e; SensorMedics) allowed the calculation of breathing pattern parameters, including tidal volume (VT), minute ventilation (
E), peak inspiratory flow to mean inspiratory flow ratio (PIFMF), and the peak expiratory flow to mean expiratory flow ratio (PEFMF). The latter parameters are considered to detect flow limitation, with values > 1.5 representing normal (rounded) RIP-derived waveforms. As the flow waveform flattens, indicating increased resistance, the values approach 1.0. SpO2, also included in the SomnoStar PT and analyzed by the same software, was evaluated simultaneously.
For each patient, measurements of VT,
E, PIFMF, PEFMF, and SpO2 were performed during 2 min in the supine position at baseline and 1 min after each MI-E application. Median values for each parameter were analyzed.
PCF were measured before the first application and after the last application by having the patient cough as forcibly as possible through a peak flowmeter (Assess; Health Scan Products; Cedar Grove, NJ). The maximum observed flows in four or five attempts were recorded.7 For evaluating the effect of treatment on dyspnea, a Borg scale (0 = not at all breathless; 10 = maximal breathlessness) was administered before and after the intervention.20
Statistical Analysis
Statistical analysis was carried out using SPSS 10.0 (SPSS; Chicago, IL). Results are expressed as median and interquartile range (IQR). Comparisons between patient groups were done using the Mann-Whitney U test and differences between baseline and MI-E settings were compared using the Wilcoxon rank test. A Spearman rank correlation coefficient was used to examine the relationship between physiologic data; p
0.05 was considered significant.
| Results |
|---|
|
|
|---|
There were no significant differences between groups in VT,
E, PIFMF, PEFMF, and SpO2 at baseline. In patients with NMD, only PCF improved significantly after MI-E (180 L/min vs 220 L/min); in patients with COPD, SpO2 improved significantly only after 40 to 40 cm H2O of MI-E (92% vs 97%). In patients with ALS, both PCF and SpO2 improved significantly after 40 to 40 cm H2O. Moreover, in this group PIFMF increased significantly between 15 to 15 cm H2O, 30 to 30 cm H2O, and 40 to 40 cm H2O (1.38 vs 1.45 and 1.38 vs 1.44). Although there was no significant difference for the rest of breathing pattern parameters during different settings for each patient group, after MI-E at 30 to 30 cm H2O, PIFMF was significantly lower in patients with COPD, compared to ALS (1.36 vs 1.44, p = 0.046).
Dyspnea (Borg scale) improved significantly after 40 to 40 cm H2O of MI-E in patients with COPD and patients with NMDs. Pulmonary parameters as a function of MI-E settings and significant comparisons are reported in Table 2 .
|
E, PIFMF, and PEFMF). In patients with ALS, we did find a positive correlation between FVC and MIP with PCF after MI-E (r = 0.720, p = 0.008, and r = 0.778, p = 0.005, respectively). The effects of MI-E on the RIP measurements of VT,
E, and SpO2 are shown in Figure 1
. No patients complained of abdominal distension or vomiting, blood-streaked sputum, chest pain, discomfort, nor had any other symptoms or signs suggestive of barotrauma at any time during or following the study.
|
| Discussion |
|---|
|
|
|---|
60 cm H2O, the great majority of patients in clinical practice receive it at 40 to 40 cm H2O. Thus, these are the widely preferred pressures in clinical practice for both comfort and effectiveness in many hundreds of patients and thousands of applications in patients with neuromuscular weakness over the last 50 years.22 Likewise, Barach and Beck23 wrote that the pulmonary pressure changes generated by MI-E are a small fraction of those generated by respiratory muscle contractions during a normal cough. Thus, it is not surprising that there was no apparent barotrauma nor other respiratory complications in this study. Breathing pattern characteristics did not deteriorate after MI-E. This is consistent with studies that reported significant increases in vital capacity and SpO2 when using MI-E to clear airway secretions.6710 In a study6 including patients with NMD, FEV1 following MI-E only increased, demonstrating no persistent airway collapse or air-trapping. The present study demonstrated that the same could be true for MI-E used in COPD when evaluating breathing parameters by RIP.
The increase in SpO2 with MI-E was not associated with other changes in RIP parameters. It is possible that the benefit of the technique, improving the recruitment of nonventilated pulmonary zones, and removing mucous debris, attains a more evident improvement in gas exchange rather than in breathing pattern. However, to answer this question it would have been necessary to examine the effects of MI-E on ventilation perfusion ratio distribution and oxygen and carbon dioxide exchange, which was beyond the aim of our study.
RIP is the most widely accepted method for quantitative and qualitative noninvasive respiratory measurements, and has been demonstrated to accurately measure VT,2425 and detect inspiratory and expiratory flow limitation or collapse.2627 The former occurs because of the narrowing or collapse of the upper airway in response to the negative intrathoracic pressure during inspiration. Clinically this is seen in patients with sleep-disordered breathing,28 and during negative-pressure ventilatory support.29 Application of negative pressure ( 5 cm H2O) at the mouth during resting tidal respiration has been shown to enhance detection of expiratory flow limitation.30
In our study, we used RIP to evaluate the effect of MI-E. In the oNMD group, we did not find any deterioration in breathing pattern or pulmonary parameters. In the ALS group, PIFMF even significantly increased with pressures at 40 to 40 cm H2O, suggesting decreased pharyngeal resistance.27 In the COPD group, the shape of flow volume waveforms were also little affected by MI-E, and median PEFMF remained constant over all the MI-E applications (Table 2). Therefore, concerns by Sivasothy et al11 that MI-E may exacerbate hyperinflation do not appear to be justified with these measurements. However, evaluation of lung volumes should be considered for more accurate conclusions.
In patients with ALS, the majority with bulbar involvement and receiving domiciliary NPPV, a significant improvement in PCF and progressive increase of SpO2 with increasing MI-E pressures was demonstrated. No subjects complained of discomfort during MI-E, and the patients with COPD actually reported relief of dyspnea (Borg scale). This is consistent with other published experiences in > 2,000 applications of MI-E, the majority of which were in patients with intrinsic lung disease.10
Although we cannot exclude a placebo effect, the significant improvement in SpO2 at the end of the last application suggested that they indeed benefited. In fact, contrary to the findings of Sivasothy el al,11 we did not find deterioration of PCF with MI-E. The differences found might be attributed to the technique of PCF measurements (pneumotachograph in the study by Sivasothy et al,11 and a standard peak flowmeter in our study), coughs performed without the exsufflation, and the significantly higher MI-E pressures used in our study. The use of lower pressures may be ineffective, as is suggested by the improvement in SpO2 in patients with COPD (as well as in other patient groups) being reached only at the highest pressure application. In fact, Gomez-Merino et al,31 using MI-E connected to a lung model, found that insufflation and exsufflation pressures of 35 to 35 cm H2O or 40 to 40 cm H2O were the most effective in achieving higher values of PCF, and these pressures are also those suggested by the manufacturer.17 These authors31 observed that because the minimally clinically effective cough flow of 2.7 L/s was not achieved at insufflation-exsufflation spans of < 30 cm H2O, settings below 30 to 30 cm H2O should not be expected to be effective. Moreover, this technique can be applied in a more aggressive protocol, for longer periods of time to obtain adequate PCFs to prevent mucus plugging and profuse airway secretions, especially during respiratory tract infections and acute respiratory failure.3233
| Conclusion |
|---|
|
|
|---|
The results of this study may indicate the use of MI-E for secretion management during ventilator weaning5 and possibly for COPD exacerbations with excessive secretions.34 Further validation is warranted in a larger patient population.
| Acknowledgements |
|---|
| Footnotes |
|---|
E = minute ventilation; VT = tidal volume Received for publication October 16, 2003. Accepted for publication April 12, 2004.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
B. Fauroux, N. Guillemot, G. Aubertin, N. Nathan, A. Labit, A. Clement, and F. Lofaso Physiologic Benefits of Mechanical Insufflation-Exsufflation in Children With Neuromuscular Diseases Chest, January 1, 2008; 133(1): 161 - 168. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |